The World Health Organization (WHO) has recommended two new prescription drugs – mAb114 (Ansuvimab, Ebanga) and REGN-EB3 (Inmazeb) based on monoclonal antibodies – to treat the diseases caused by the Ebola virus.

Report informs, citing TASS, that based on a systematic review and meta-analysis of randomized clinical drug trials, WHO has issued a strong recommendation for the use of these drugs in Ebola disease. Janet Diaz, Head of WHO Clinical Care, said at a briefing in Geneva on Friday that Ansuvimab and Inmazeb reduce patient mortality by 60%. These drugs have been tested during the Ebola outbreaks in Africa. In particular, the largest study was conducted in the Democratic Republic of the Congo (DRC).